BEONTAG
17.1.2023 12:01:56 CET | Business Wire | Press release
Today, Beontag – one of the world’s largest manufacturers of self-adhesives and smart tags (such as digital labels, and labeling technology solutions like RFID and NFC) – announced that Tags Lux Sarl., a wholly owned subsidiary of the Company, has secured and closed a binding agreement for a syndicated loan of €120 million with global banks and Deutsche Bank as sole lead arranger.
Beontag, the second largest provider of digital RFID and NFC solutions for some of the world’s biggest fashion and consumer brands, is expected to achieve €550 Million in revenue for 2022, with international and national acquisitions, integrations and expansion contributing to significant top-line growth from pro forma actualized revenues of more than €400 Million in 2021. This is the first significant, international capital raise by the Brazilian-founded company – with operations now spanning more than 15 international facilities and a presence in over 40 countries.
Terms of Syndicated Facility
- The syndicated loan shall mature within 60 months from closing date with 18 months grace period, including a possibility of prepayment from the 18th month.
- Beontag intends to use the net proceeds from the issuance to primarily refinance its existing debt throughout the group. Any excess proceeds will be used to support organic strategic initiatives across multiple geographies and enhance liquidity.
- The transaction is expected to be leverage-neutral after closing.
- The loan shall carry an interest rate of EURIBOR plus 4.5% per annum and contains incentivised terms that are linked to Beontag 2030 ESG strategy, which is aligned to the United Nations Sustainable Development Goals (SDGs). Every year, Beontag will seek third-party verification to certify and report upon progress against the ESG-related terms agreed.
Global Expansion, Borderless Solutions
Beontag’s Chief Financial Officer, Pedro Christ, commented: “Investment is a key aspect of our journey to become a truly borderless, end-to-end solutions provider of self-adhesive label stock and IoT solutions. And we believe this syndicated capital raise is a good example of the confidence of international investors in Beontag’s global strategy, as well as our current operational fundamentals.
For 2023, and beyond, we are excited to continue to innovate and expand our solutions to meet our clients’ demands for future-focused support, all while taking care to improve our ESG credentials and reduce the impact of our sector on the planet.”
The Managing Director of Global Emerging Markets from Deutsche Bank, Ricardo Cunha, added: “We are delighted to partner with Beontag for this transaction. This commitment, with and added ESG incentive, reflects our confidence in both the strength and sustainable intention of their innovative plans for the sector.
We look forward to keep supporting Beontag as the company expands into different markets and geographies.”
ENDS
ABOUT BEONTAG
For more than 40 years, Beontag has been dedicated to developing the future of pressure sensitive label stock and RFID technology, being world leaders in both segments. Today the company’s dedicated team, leading technology, global reach, and capabilities help the world work more efficiently, reliably, and safely. Beontag´s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill Beontag´s mission to be a digital enabler.
With modern manufacturing facilities, permanent investment and a highly qualified team, the company has been expanding its business globally and is one of the largest and most respected self-adhesive companies in Latin America. It also operates in the technology sector and has a wide portfolio of Internet of Things (IoT) solutions, focused on the manufacture of radiofrequency smart labels, as well as on the development of software for the integration of the logistics chain, traceability, and product authentication.
To learn more, visit: https://beontag.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom